Abstract: Objective To observe the efficacy of compound embryonic bovine liver extract tablets in treatment of patients with chronic hepatitis B（CHB）. Methods One hundred and twenty patients with CHB were recruited, and divided randomly into control group（n=56）or treatment group （n=64）;Patients in control group were treated with basic liver-protecting treatment and patients in treatment group were treated with combinational therapy of compound embryonic bovine liver extract tablets and basic treatment. Changes in liver function tests and fibrotic parameters were examed after 3 months of treatment. Results At the end of 3 months of treatment,the fatigue and poor appetite were improved in 92.00% and 91.84%,respectively,in treatment group,significantly higher than those in controls（56.41% and 58.33%,respectively,P<0.05）;the serum ALT, AST, GGT and total bilirubin levels in treatment group were （35.6±17.2） U/L,（38.5±18.6） U/L,（40.6±19.7） U/L and （16.1±13.9） μmol/L,respectively,significantly decreased than those before treatment [（110.8±61.4） U/L for ALT,（97.2±62.4） U/L for AST,（106.3±60.1） U/L for GGT and（47.8±19.3） μmol/L for total bilirubin,P<0.05];serum PIIIP（36.7±11.3 μg/L）, HA （276.4±79.5 μg/L）,LN（169.8±73.4 μg/L） and IV-C （155.8±61.5 μg/L） in treatment group decreased significantly than those before treatment[（16.4±6.1） μg/L for PIIIP,（110.8±51.4） μg/L for HA,（70.8±34.9） μg/L for LN and（97.8±41.4） μg/L for IV-C,P<0.05],which lowered more obviously than in control. Conclusion Compound embryonic bovine liver extract may be a promising therapeutic remedy for patients with CHB.

Key words: Chronic hepatitis B, Compound embryonic bovine liver extract tablets, Therapy